The approval of new cancer drugs is a rigorous process governed by regulatory bodies like the FDA in the United States or the EMA in Europe. These agencies review data from clinical trials to ensure that new drugs are both safe and effective. The approval process includes several phases of clinical trials, post-marketing surveillance, and continuous monitoring to ensure long-term safety.
